Randomized, Controlled, Multicenter Study of Neoadjuvant Therapy With Icotinib in IIIA NSCLC Patients With Epidermal Growth Factor Receptor Mutation

Trial Profile

Randomized, Controlled, Multicenter Study of Neoadjuvant Therapy With Icotinib in IIIA NSCLC Patients With Epidermal Growth Factor Receptor Mutation

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2015

At a glance

  • Drugs Icotinib (Primary) ; Cisplatin; Vinorelbine
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Zhejiang Beta Pharma
  • Most Recent Events

    • 14 Jul 2015 Planned End Date changed from 1 Feb 2017 to 1 Feb 2018 as reported by ClinicalTrials.gov record.
    • 14 Jul 2015 Planned primary completion date changed from 1 Feb 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
    • 26 Jun 2014 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top